About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist

AI Drug Discovery Stocks watchlist Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users. However, that may have hit a peak as traffic started toNASDAQ: GOOGL"> unwind in June 2023 as ChatGPT traffic fell off for the first time since its launch. AI is still evolving with its applications and use cases. One area that has materially gained from AI is the drug discovery segment.

AI Optimizing Drug Discovery

AI has optimized the tedious, complex task of finding targets, matching millions of potential combinations and indications to derive treatments that can take upwards of $2.5 billion and 10 to 15 years to bring a drug to market successfully. AI-powered drug discovery saves time and costs by speeding up the discovery, analysis, preclinical testing and clinical trials process. It can predict the safety and efficacy of new drugs even before clinical trials commence.

Here are three of the most promising AI drug discovery companies on your radar.

Schrodinger stock chart

Schrodinger Inc. (NASDAQ: SDGR)

Schrodinger is one of the oldest leading drug discovery companies. It was started in 1990 and is based in New York. It operates two segments Software and Drug Discovery. Its cloud-based AI and machine learning (ML) platform helps researchers and scientists create and design new drugs by predicting interactions of molecular properties.

Its technology can dock small molecules to proteins and simulate their behaviors. The company already has two FDA-approved drugs, Obxbryta for sickle cell, approved in 2019, and Accolate for asthma in 1998. It has various oncology and immunology treatments in its pipeline like SGR-1505 to relapse/resistance non-Hodgkin's lymphoma, SGR-2921 for solid tumors and hematological cancers, SGR-3515 for gynecological cancers and LRRK2 for Parkinson's disease.

Schrodinger analyst ratings and price targets are at MarketBeat.

Recursion Pharmaceuticals stock price

Recursion Pharmaceuticals (NASDAQ: RXRX)

Recursion made big headlines and a monstrous spike on news of a $50 million PIPE investment from NVIDIA Co. (NASDAQ: NVDA). Recursion has over 23 petabytes of proprietary biological and chemical data on its Recursion Data Universe. Its Recursion Map has hundreds of billions of searchable chemistry and biological inferences supporting millions of weekly wet lab experiments. These are lab experiments using "wet" materials, which are chemical, liquid, biological and fluid samples.

Some of the common wet labs include cell cultures, DNA sequencing, gene expression analysis, protein purification and drug discovery. Recursion has four clinical trials and many preclinical projects targeting cancers and diseases.

It beefed up its AI with the $87 million combined acquisition of digital chemistry suite Cyclica and AI/ML chemistry prediction company Valence. Recursion will use NVDIA's BioNeMo platform for commercial licensing and release of its AI models.

Recursion Pharmaceuticals analyst ratings and price targets are at MarketBeat.

Exscientia stock chart

Exscientia PLC (NASDAQ: EXAI)

UK-based Exscientia is a pharmatech AI drug discovery company developing small molecule targets for hematological and inflammatory diseases, Alzheimer's and various cancers. The company pioneered personalized precision medicine to target specific receptors instrumental in inflammation, pain and cancer.

Some of its big-dollar collaborations include a lucrative partnership with Sanofi (NASDAQ: SNY) to develop up to 15 small molecules worth up to $5.2 billion in milestone and royalty payments.

Sanofi provided $100 million in upfront payments with the potential to earn up to $343 million per small molecule, comprised of $193 million for research and development and upwards of $150 million for achieving commercial milestones.

Bristol Myer-Squibb PKC-theta Targeting

Exscientia also partners with Bristol Myers-Squibb Co. (NYSE: BMY), targeting a key protein instrumental in many inflammatory, immunological and autoimmune diseases called PKC-theta. It's also collaborating on a promising therapy to reduce amyloid plaque in the brain, which is believed to be a main contributor to Alzheimer's disease. Its EXS74539 has shown some success in animal models of Alzheimer's by improving cognitive functions.

Collaboration with GT Apeiron

Its latest milestone is enrolling the first human patient in its trials of ELUCIDATE for treating advanced solid tumors in colorectal, hand and neck, breast and ovarian and non-small cell lung cancer patients. This is achieved by blocking the CDK7 protein. It's partnered with Chinese biotech company GT Apeiron on the study.

Exscientia analyst ratings and price targets are at MarketBeat.

 

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.